锑葡胺
婴儿利什曼原虫
内脏利什曼病
医学
犬利什曼病
免疫疗法
药理学
单克隆抗体
免疫学
化疗
利什曼病
抗体
内科学
免疫系统
作者
Jamille Mirelle de Oliveira Cardoso,Rory Cristiane Fortes de Brito,Fernando Augusto Siqueira Mathias,Levi Eduardo Soares Reis,João Filipe Pereira Vieira,Thais Lopes Valentim Di Paschoale Ostolin,Hélida Monteiro de Andrade,Guilherme Santos Ramos,Frédéric Frézard,Rodrigo Dian de Oliveira Aguiar‐Soares,Bruno Mendes Roatt,Alexandre Barbosa Reis
标识
DOI:10.1016/j.molimm.2021.11.011
摘要
This study compared the therapeutic potential of the chemotherapy using meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes (Nano Sbv) and immunotherapy with anti-canine IL-10 receptor-blocking monoclonal antibody (Anti IL-10R) on canine visceral leishmaniasis (CVL). Twenty mongrel dogs naturally infected by L. infantum, displaying clinical signs of visceral leishmaniasis were randomly divided in two groups. In the first one, nine dogs received six intravenous doses of a mixture of conventional and PEGylated liposomes containing meglumine antimoniate at 6.5 mg Sb/kg/dose. In the second one, eleven dogs received two intramuscular doses of 4 mg of anti-canine IL-10 receptor-blocking monoclonal antibody. The animals were evaluated before (T0) and 30, 90, and 180 days after treatments. Our major results demonstrated that both treatments were able to maintain hematological and biochemical parameters, increase circulating T lymphocytes subpopulations, increase the IFN-γ producing T-CD4 lymphocytes, restore the lymphoproliferative capacity and improve the clinical status. However, although these improvements were observed in the initial post-treatment times, they did not maintain until the end of the experimental follow-up. We believe that the use of booster doses or the association of chemotherapy and immunotherapy (immunochemotherapy) is promising to improve the effectiveness of treating CVL for improving the clinical signs and possibly reducing the parasite burden in dogs infected with Leishmania infantum.
科研通智能强力驱动
Strongly Powered by AbleSci AI